5-androstene-3β,7β,17β-triol (β-aet) slows thermal injury induced osteopenia in mice: Relation to aging and osteoporosis

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Malik, Ajay K ^a   Khaldoyanidi, Sophia ^b   Auci, Dominick L ^a   Miller, Scott C ^c   Ahlem, Clarence N ^a   Reading, Christopher L ^a   Page, Theodore ^a   Frincke, James M ^a  

^a Harbor Biosciences Inc   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ANDROSTENE 3BETA,7BETA,17BETA TRIOL; ANDROSTANE DERIVATIVE; GLUCOCORTICOID; PRASTERONE; UNCLASSIFIED DRUG; 5 ANDROSTENE 3,7,17 TRIOL; 5-ANDROSTENE-3,7,17-TRIOL;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERAL; CARTILAGE CELL; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH PLATE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; THERMAL INJURY; TISSUE REGENERATION; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; BURN; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; METABOLIC BONE DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; TUMOR CELL LINE;

MURINAE; MUS;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; AGING; ANDROSTENOLS; ANIMALS; BONE DISEASES, METABOLIC; BURNS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; OSTEOPOROSIS;

EID: 78149455415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013566     Document Type: Article

References (80)

1. Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK (2006) The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 38: 89-116.
2. Svec F, Porter JR (1998) The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218: 174-191.
3. Auci DL, Ahlem C, Li M, Trauger R, Dowding C, et al. (2003) The immunobiology and therapeutic potential of androstene hormones and their synthetic derivatives: novel anti-inflammatory and immune regulating steroid hormones. Mod Asp Immunobiol 3: 64-70.
4. Cleary MP (1991) The antiobesity effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med 196: 8-16.
5. Araneo BA, Woods ML2nd Daynes RA (1993) Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. J Infect Dis 167: 830-840.
6. Canning MO, Grotenhuis K, de Wit HJ, Drexhage HA (2000) Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocytederived dendritic cells [In Process Citation]. Eur J Endocrinol 143: 687-695.
7. Clerici M, Trabattoni D, Piconi S, Fusi ML, Ruzzante S, et al. (1997) A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinology 22: S27-31.
8. Harding G, Mak YT, Evans B, Cheung J, Macdonald D, et al. (2006) The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: Potential steroid-sparing role for DHEA. Cytokine 36: 57-68.
9. Wang L, Wang YD, Wang WJ, Zhu Y, Li DJ (2007) Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol 38: 467-479.
10. Bovenberg SA, van Uum SH, Hermus AR (2005) Dehydroepiandrosterone administration in humans: evidence based? Neth J Med 63: 300-304.
11. Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, et al. (2004) The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum 50: 3591-3595.
12. Sanchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, et al. (2008) Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 35: 1567-1575.
13. von Muhlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R (2008) Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int 19: 699-707.
14. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, et al. (2006) Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 91: 2986-2993.
15. Labrie F, Luu-The V, Belanger A, Lin SX, Simard J, et al. (2005) Is dehydroepiandrosterone a hormone? J Endocrinol 187: 169-196.
16. Takayanagi R, Goto K, Suzuki S, Tanaka S, Shimoda S, et al. (2002) Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts. Mech Ageing Dev 123: 1107-1114.
17. Wolf OT, Kirschbaum C (1999) Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev 30: 264-288.
18. Marwah A, Marwah P, Lardy H (2002) Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J Chromatogr B Biomed Sci Appl 767: 285-299.
19. Hammer F, Subtil S, Lux P, Maser-Gluth C, Stewart PM, et al. (2005) No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. J Clin Endocrinol Metab 90: 3600-3605.
20. Lardy H, Marwah A, Marwah P (2002) Transformations of DHEA and its metabolites by rat liver. Lipids 37: 1187-1191.
21. Lardy H, Marwah A, Marwah P (2005) C(19)-5-ene Steroids in Nature. Vitam Horm 71: 263-299.
22. Cui H, Lin SY, Belsham DD (2003) Evidence that dehydroepiandrosterone, DHEA, directly inhibits GnRH gene expression in GT1-7 hypothalamic neurons. Mol Cell Endocrinol 203: 13-23.
23. Lardy H (2003) Happily at work. J Biol Chem 278: 3499-3509.
24. Rose KA, Stapleton G, Dott K, Kieny MP, Best R, et al. (1997) Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7alpha-hydroxy dehydroepiandrosterone and 7alpha-hydroxy pregnenolone. Proc Natl Acad Sci U S A 94: 4925-4930.
25. Martin C, Bean R, Rose K, Habib F, Seckl J (2001) cyp7b1 catalyses the 7alpha- hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate. Biochem J 355: 509-515.
26. Auci DL, Reading CL, Frincke JM (2009) 7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. Autoimmun Rev 8: 369-372.
27. Davidson M, Marwah A, Sawchuk RJ, Maki K, Marwah P, et al. (2000) Safety and pharmacokinetic study with escalating doses of 3-acetyl-7- oxo-dehydroepi-androsterone in healthy male volunteers [In Process Citation]. Clin Invest Med 23: 300-310.
28. Davidson MH, Weeks CE, Lardy H, Maki K, Umporowicz D (1998) Safety and endocrine effects of 3-acetyl-7-oxo DHEA (7-Keto-DHEA) FASEB Journal;, 1998 April 18-22;San Francisco, CA. pp A764, abstract 4429.
29. Loria RM (1997) Antiglucocorticoid function of androstenetriol. Psychoneur- oendocrinology 22: S103-108.
30. Padgett DA, Loria RM (1994) In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenetriol. J Immunol 153: 1544-1552.
31. Padgett DA, Loria RM (1998) Endocrine regulation of murine macrophage function: effects of dehydroepiandrosterone, androstenediol, and androstenetriol. J Neuroimmunol 84: 61-68.
32. Padgett DA, Sheridan JF, Loria RM (1995) Steroid hormone regulation of a polyclonal TH2 immune response. Ann N Y Acad Sci 774: 323-325.
33. Bowman BM, Hooper CC, Shelby J, Miller SC (2001) Comparison of an injury stress-response on skeletal growth in two inbred strains of mice; 2001; Madrid, Spain: European Calcified Tissue Society. pp P62 T.
34. Edelman LS, Shao W, Miller S, Bowman B, Morris SE, et al. (1997) The 1997 Lindberg Award. Effects of burn injury on bone and growth in a mouse model. J Burn Care Rehabil 18: 483-489.
35. Miller SC, Bowman BM, Siska CC, Shelby J (2002) Effects of thermal injury on skeletal metabolism in two strains of mice. Calcif Tissue Int 71: 429-436.
36. Reyes M, Verfaillie M (2001) Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 938: 231-233; discussion 233-235.
37. Bruder SP, Jaiswal N, Haynesworth SE (1997) Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 64: 278-294.
38. Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, et al. (2005) 11beta- Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 19: 621-631.
39. Kalak R, Zhou H, Street J, Day RE, Modzelewski JR, et al. (2009) Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice. Bone.
40. Sher LB, Harrison JR, Adams DJ, Kream BE (2006) Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int 79: 118-125.
41. Sher LB, Woitge HW, Adams DJ, Gronowicz A, Krozowski Z, et al. (2004) Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology 145: 922-929.
42. Zhou H, Mak W, Zheng Y, Dunstan CR, Seibel MJ (2008) Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem 283: 1936-1945.
43. Mushtaq T, Farquharson C, Seawright E, Ahmed SF (2002) Glucocorticoid effects on chondrogenesis, differentiation and apoptosis in the murine ATDC5 chondrocyte cell line. J Endocrinol 175: 705-713.
44. Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R (1995) Toward a molecular understanding of skeletal development. Cell 80: 371-378.
45. Marks SC, Jr., Lundmark C, Christersson C, Wurtz T, Odgren PR, et al. (2000) Endochondral bone formation in toothless (osteopetrotic) rats: failures of chondrocyte patterning and type X collagen expression. Int J Dev Biol 44: 309-316.
46. Goddard MS, Reid KR, Johnston JC, Khanuja HS (2009) Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 32.
47. Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ (2009) Case Reports: ubtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy. Clin Orthop Relat Res.
48. Boyce BF, Xing L (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9(Suppl 1): S1.
49. Corral DA, Amling M, Priemel M, Loyer E, Fuchs S, et al. (1998) Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci U S A 95: 13835-13840.
50. Dovio A, Perazzolo L, Saba L, Termine A, Capobianco M, et al. (2006) High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol 154: 745-751.
51. Buxton EC, Yao W, Lane NE (2004) Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 89: 3332-3336.
52. Korczowska I, Olewicz-Gawlik A, Hrycaj P, Lacki J (2003) The effect of long- term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: the prevalence of its anti-inflammatory action upon bone resorption. Yale J Biol Med 76: 45-54.
53. Sahin G, Ozturk C, Bagis S, Cimen OB, Erdogan C (2002) Correlation of serum cytokine levels with axial bone mineral density. Singapore Med J 43: 576-578.
54. Dovio A, Sartori ML, Masera RG, Peretti L, Perotti L, et al. (2004) Effects of physiological concentrations of steroid hormones and interleukin-11 on basal and stimulated production of interleukin-8 by human osteoblast-like cells with different functional profiles. Clin Exp Rheumatol 22: 79-84.
55. Urban NH, Chamberlin B, Ramage S, Roberts Z, Loria RM, et al. (2008) Effects of alpha/beta-androstenediol immune regulating hormones on bone remodeling and apoptosis in osteoblasts. J Steroid Biochem Mol Biol 110: 223-229.
56. Gunther T, Schule R (2007) Fat or bone? A non-canonical decision. Nat Cell Biol 9: 1229-1231.
57. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, et al. (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31: 845-851.
58. McDonough AK, Rosenthal RS, Cao X, Saag KG (2008) The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab 4: 507-513.
59. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, et al. (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168: 820-825.
60. Yaturu S, Bryant B, Jain SK (2007) Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30: 1574-1576.
61. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, et al. (2004) Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 5: 1007-1012.
62. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, et al. (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113: 846-855.
63. Loria RM, Padgett DA, Huynh PN (1996) Regulation of the immune response by dehydroepiandrosterone and its metabolites. J Endocrinol 150(Suppl): S209-220.
64. Klein GL (2006) Burn-induced bone loss: importance, mechanisms, and management. J Burns Wounds 5: e5.
65. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE (2000) The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 85: 883-889.
66. Przkora R, Herndon DN, Sherrard DJ, Chinkes DL, Klein GL (2007) Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. Bone 41: 297-302.
67. Tamasi V, Miller KK, Ripp SL, Vila E, Geoghagen TE, et al. (2008) Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Mol Pharmacol 73: 968-976.
68. Daynes RA, Jones DC (2002) Emerging roles of ppars in inflammation and immunity. Nat Rev Immunol 2: 748-759.
69. Wang T, Villegas S, Huang Y, White SK, Ahlem C, et al. Amelioration of Glucose Intolerance by the Synthetic Androstene HE3286: Link to Inflammatory Pathways. J Pharmacol Exp Ther.
70. Liu D, Dillon JS (2004) Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 69: 279-289.
71. Vicent GP, Ballare C, Nacht AS, Clausell J, Subtil-Rodriguez A, et al. (2008) Convergence on chromatin of non-genomic and genomic pathways of hormone signaling. J Steroid Biochem Mol Biol 109: 344-349.
72. Benten WP, Stephan C, Lieberherr M, Wunderlich F (2001) Estradiol signaling via sequestrable surface receptors. Endocrinology 142: 1669-1677.
73. Foradori CD, Weiser MJ, Handa RJ (2008) Non-genomic actions of androgens. Front Neuroendocrinol 29: 169-181.
74. Stewart PM, Mason JI (1995) Cortisol to cortisone: glucocorticoid to mineralocorticoid. Steroids 60: 143-146.
75. Nashev LG, Chandsawangbhuwana C, Balazs Z, Atanasov AG, Dick B, et al. (2007) Hexose-6-phosphate dehydrogenase modulates 11beta-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto- and 7beta-hydroxy-neurosteroids. PLoS ONE 2: e561.
76. Balazs Z, Schweizer RA, Frey FJ, Rohner-Jeanrenaud F, Odermatt A (2008) DHEA induces 11 -HSD2 by acting on CCAAT/enhancer-binding proteins. J Am Soc Nephrol 19: 92-101.
77. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 43-47.
78. Feldman BJ (2009) Glucocorticoids influence on mesenchymal stem cells and implications for metabolic disease. Pediatr Res 65: 249-251.
79. Kolf CM, Cho E, Tuan RS (2007) Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther 9: 204.
80. Croisille L, Auffray I, Katz A, Izac B, Vainchenker W, et al. (1994) Hydrocortisone differentially affects the ability of murine stromal cells and human marrow-derived adherent cells to promote the differentiation of CD34++/CD38- long-term culture-initiating cells. Blood 84: 4116-4124.